Patents Assigned to New York Blood Center, Inc.
  • Patent number: 5723293
    Abstract: The invention provides a diagnostic method of determining Rh genotypes by the identification of the molecular basis of Rh polymorphisms. Specifically, the invention provides a method for directly determining Dd and associated CcEe genotypes with great accuracy, overcoming problems associated with traditional serologic typing methods and leading to a direct discrimination of D/D, D/d, and d/d genetic status. The diagnostic method allows genotyping of fetuses to assess the risk of hemolytic diseases caused by Rh alloimmunization and genetic counseling and/or testing of couples to predict the outcome of pregnancies in relation to Rh incompatibilities. The method of the invention preferably employs amplification of Rh nucleic acid sequences, and employs differential cleavage of RhD-, RhCc- and/or RhEe-specific nucleic acid sequences by a restriction enzyme. Furthermore, diagnostic kits for the determination of Rh genotypes are provided.
    Type: Grant
    Filed: November 6, 1995
    Date of Patent: March 3, 1998
    Assignee: The New York Blood Center, Inc.
    Inventor: Cheng-Han Huang
  • Patent number: 5712086
    Abstract: A process is presented for transfusing cells which have been sterilized with radiation and a quencher of type I and type II photodynamic reactions. The cells are removed from a donor and exposed to virucidally effective amount of radiation in the presence of a quencher of type I and type II reactions, or a mixture of a quencher for type I reactions and a quencher of type II reactions. Subsequently, the sterilized cell containing fraction is returned to the donor.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 27, 1998
    Assignee: New York Blood Center, Inc.
    Inventors: Bernard Horowitz, Bolanle Williams, Henrietta Margolis-Nunno, Sing N. Chin
  • Patent number: 5683696
    Abstract: gpD protein, the major subunit of the Duffy blood group antigenic system, has been isolated. gpD protein contains the receptor, by which P. vivax enters red cells and causes malaria. gpD has significant sequence homology with human and rabbit interleukin-8 receptors and, therefore, gpD protein likely is a new class of chemoattractant cytokines receptor. gpD protein cDNA has a quasi-total homology with a human hippocampus cDNA clone HHCMF86 and, therefore, gpD protein or a homologous protein may be present as a neuropeptide receptor in brain. gpD protein is present in all red cell progenitors and it may be a receptor for cell proliferation and/or differentiation. gpD protein cDNA identifies in human kidney a mRNA of the same size as the bone marrow. Since the kidney is not and has no potential to become an erythropoietic organ, this putative chemoattractant receptor may have essential renal functions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 4, 1997
    Assignee: New York Blood Center, Inc.
    Inventors: Angel Oscar Pogo, Asok Chaudhuri
  • Patent number: 5677162
    Abstract: The present invention provides a method for activating prothrombin to thrombin in a prothrombin complex composition comprising at least prothrombin, Factors V, VII, IX, and X, and phospholipid, comprising the steps of: (a) cold-incubating the prothrombin complex composition with 2-15 mM of Ca.sup.2+ ions at a pH of 6.5-8.0 and at a temperature of 2.degree.-8.degree. C. until Factor VII contained in the composition is activated; and (b) incubating the cold-incubated composition at a pH of 6.5-8.0 and at a temperature of 10.degree.-25.degree. C. for a period of time sufficient to activate prothrombin contained in the composition to thrombin.
    Type: Grant
    Filed: May 1, 1995
    Date of Patent: October 14, 1997
    Assignee: New York Blood Center, Inc.
    Inventors: Jinsheng Zou, John Hamman, Gerard Marx, Bernard Horowitz
  • Patent number: 5658722
    Abstract: An improvement in a process for inactivating extracellular and intracellular viruses in a platelet containing composition is presented. The improvement in the process comprises adding a sensitizer to the platelet containing composition and irradiating the composition containing the sensitizer with UVA1 in the absence of UVA2 for a period of time sufficient to inactivate the viruses while retaining the functionality of the platelet containing composition. A quencher or mixture of quenchers of type I and type II photodynamic reactions may be advantageously added to the composition prior to irradiation.
    Type: Grant
    Filed: November 25, 1994
    Date of Patent: August 19, 1997
    Assignee: New York Blood Center, Inc.
    Inventors: Henrietta Margolis-Nunno, Ehud Ben-Hur, Bernard Horowitz
  • Patent number: 5651982
    Abstract: The present invention describes a biologically compatible bioadhesive sealant composition comprising fibrin glue and liposomes for use in mammals, including humans. Fibrin glue of the invention comprises fibrinogen and thrombin which are mixed together in various modes with liposomes and applied to a site of injury, to a wound, or to a surgical or nonsurgical incision or opening. In accordance with the invention, the liposomes are embedded within the fibrin glue after coagulation has occurred, and may release bioactive substances contained within their aqueous interiors to promote healing and protection during the recovery process. The bioadhesive composition of the invention promises to maintain hemostasis after surgeries and improves upon existing glues or gel formulations due to its complete biological compatibility, its formation in situ, and its provision of bioactive therapeutics via entrapped liposomes directly to the site.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 29, 1997
    Assignee: New York Blood Center, Inc.
    Inventor: Gerard Marx
  • Patent number: 5637451
    Abstract: An improved process for inactivating an extracellular lipid enveloped virus or an intracellular lipid enveloped virus which may be present in an extracorporeal composition containing red blood cells by subjecting the composition to a virucidally effective amount of a phthalocyanine compound and red light of a fluence rate of at least above about 5 mW/cm.sup.2. Quite contrary to what would have been expected, it has been found that higher light fluence rates are, in fact, more protective of red blood cells than are lower light fluence rates.
    Type: Grant
    Filed: March 29, 1995
    Date of Patent: June 10, 1997
    Assignee: New York Blood Center, Inc.
    Inventors: Ehud Ben-Hur, Bernard Horowitz
  • Patent number: 5631019
    Abstract: The present invention describes a biologically compatible bioadhesive sealant composition comprising fibrin glue and liposomes for use in mammals, including humans. Fibrin glue of the invention comprises fibrinogen and thrombin which are mixed together in various modes with liposomes and applied to a site of injury, to a wound, or to a surgical or nonsurgical incision or opening. In accordance with the invention, the liposomes are embedded within the fibrin glue after coagulation has occurred, and may release bioactive substances contained within their aqueous interiors to promote healing and protection during the recovery process. The bioadhesive composition of the invention promises to maintain hemostasis after surgeries and improves upon existing glues or gel formulations due to its complete biological compatibility, its formation in situ, and its provision of bioactive therapeutics via entrapped liposomes directly to the site.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: May 20, 1997
    Assignee: New York Blood Center, Inc.
    Inventor: Gerard Marx
  • Patent number: 5607694
    Abstract: The present invention describes a biologically compatible bioadhesive sealant composition comprising fibrin glue and liposomes for use in mammals, including humans. Fibrin glue of the invention comprises fibrinogen and thrombin which are mixed together in various modes with liposomes and applied to a site of injury, to a wound, or to a surgical or nonsurgical incision or opening. In accordance with the invention, the liposomes are embedded within the fibrin glue after coagulation has occurred, and may release bioactive substances contained within their aqueous interiors to promote healing and protection during the recovery process. The bioadhesive composition of the invention promises to maintain hemostasis after surgeries and improves upon existing glues or gel formulations due to its complete biological compatibility, its formation in situ, and its provision of bioactive therapeutics via entrapped liposomes directly to the site.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: March 4, 1997
    Assignee: New York Blood Center, Inc.
    Inventor: Gerard Marx
  • Patent number: 5578714
    Abstract: gpD protein, the major subunit of the Duffy blood group antigenic system, has been isolated. gpD protein contains the receptor, by which P. vivax enters red cells and causes malaria. gpD has significant sequence homology with human and rabbit interleukin-8 receptors and, therefore, gpD protein likely is a new class of chemoattractant cytokines receptor. gpD protein cDNA has a quasi-total homology with a human hippocampus cDNA clone HHCMF86 and, therefore, gpD protein or a homologous protein may be present as a neuropeptide receptor in brain. gpD protein is present in all red cell progenitors and it may be a receptor for cell proliferation and/or differentiation. gpD protein cDNA identifies in human kidney a mRNA of the same size as the bone marrow. Since the kidney is not and has no potential to become an erythropoietic organ, this putative chemoattractant receptor may have essential renal functions.
    Type: Grant
    Filed: October 21, 1993
    Date of Patent: November 26, 1996
    Assignee: New York Blood Center, Inc.
    Inventors: Angel O. Pogo, Asok Chaudhuri
  • Patent number: 5565548
    Abstract: A hepatitis B vaccine containing a peptide with an amino acid chain of at least six consecutive amino acids within the pre-S gene coded region of the envelope of hepatitis B virus. The vaccine being free of an amino acid sequence corresponding to the naturally occurring envelope proteins of hepatitis B virus and a physiologically acceptable diluent. The peptide being free or linked to a carrier. The carrier being a conventional carrier or a novel carrier including a lipid vesicle stabilized by cross-linking and having covalently bonded active sites on the outer surface thereon. Such novel carrier being useful not only to link the novel peptide containing an amino acid chain with amino acids within the pre-S gene coded region of the surface antigen of hepatitis B virus, but can also be used to bind synthetic peptide analogues of other viral proteins, as well as bacterial, allergen and parasitic proteins of man and animals.
    Type: Grant
    Filed: March 15, 1993
    Date of Patent: October 15, 1996
    Assignees: New York Blood Center, Inc., California Institute of Technology
    Inventors: Alexander R. Neurath, Stephen B. H. Kent
  • Patent number: 5541294
    Abstract: This invention relates to methods of removing undesired antibodies from blood-derived compositions containing both the antibodies and coagulation factors, such that the coagulation factors are substantially retained in the composition. The undesired antibodies may be blood group antibodies. This invention also relates to compositions in which undesired antibodies have been removed and desired coagulation factors are retained. This invention further relates to methods of inactivating virus and removing undesired antibodies from blood-derived compositions containing virus, antibodies and coagulation factors without removing coagulation factors therefrom, and to the resulting compositions.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: July 30, 1996
    Assignee: New York Blood Center, Inc.
    Inventors: Bernard Horowitz, Sing N. Chin
  • Patent number: 5514647
    Abstract: A stable and soluble multi-dose ophthalmic solution is disclosed. The solution contains fibronectin, an amino acid, a sugar, and a lower alkyl p-hydroxybenzoate. A method treatment of ophthalmic wounds employing the ophthalmic solution, a process for preparing fibronectin for ophthalmic use, a method of lyophilizing an aqueous solution of fibronectin free of albumin, a method for inhibiting bacterial growth in an ophthalmic solution while preserving the cellular adhesion and wound healing activities of fibronectin, and a method of treatment of ophthalmic wounds administering a wound-healing accelerator solution are also disclosed.
    Type: Grant
    Filed: June 1, 1994
    Date of Patent: May 7, 1996
    Assignees: New York Blood Center, Inc., JCR Pharmaceuticals Co., Ltd., Santen Pharmaceutical Co., Ltd.
    Inventors: Bernard Horowitz, Richard W. Shulman, Adrianne J. Setton, Toyohiko Nishimura, Yoichi Kawashima
  • Patent number: 5478738
    Abstract: This invention relates to an improved method of purifying the enzyme .alpha.-N-acetylgalactosaminidase from avian liver, as well as to the purified enzyme. The enzyme is capable of removing A antigens from the surface of cells in blood products. The method of purifying the enzyme is simple and time efficient, and lends itself to large scale production.
    Type: Grant
    Filed: February 8, 1994
    Date of Patent: December 26, 1995
    Assignee: New York Blood Center, Inc.
    Inventors: Jack Goldstein, Rosa S. Hurst
  • Patent number: 5411885
    Abstract: Methods of embedding and culturing tissue employing a fibrin glue composition of 2 to 100 mg/ml fibrinogen, 1 to 200 U/ml fibrinogen-activating enzyme, and 1 to 30 mM Ca(II) compound, are disclosed.
    Type: Grant
    Filed: December 17, 1993
    Date of Patent: May 2, 1995
    Assignee: New York Blood Center, Inc.
    Inventor: Gerard Marx
  • Patent number: 5348939
    Abstract: A stable and soluble multi-dose ophthalmic solution is disclosed. The solution contains fibronectin, an amino acid, a sugar, and a lower alkyl p-hydroxybenzoate. A method of treatment of ophthalmic wounds employing the ophthalmic solution, a process for preparing fibronectin for ophthalmic use, a method of lyophilizing an aqueous solution of fibronectin free of albumin, a method for inhibiting bacterial growth in an ophthalmic solution while preserving the cellular adhesion and wound healing activities of fibronectin, and a method of treatment of ophthalmic wounds administering a wound-healing accelerator solution are also disclosed.
    Type: Grant
    Filed: May 11, 1993
    Date of Patent: September 20, 1994
    Assignees: New York Blood Center, Inc., JCR Pharmaceuticals Co., Ltd., Santen Pharmaceutical Co., Ltd.
    Inventors: Bernard Horowitz, Richard W. Shulman, Adrianne J. Setton, Toyohiko Nishimura, Yoichi Kawashima
  • Patent number: 5204096
    Abstract: A hepatitis B vaccine containing a peptide with an amino acid chain of at least six consecutive amino acids within the pre-S gene coded region of the envelope of hepatitis B virus. The vaccine being free of an amino acid sequence corresponding to the naturally occurring envelope proteins of hepatitis B virus and a physiologically acceptable diluent. The peptide being free or linked to a carrier. The carrier being a conventional carrier or a novel carrier including a lipid vesicle stabilized by cross-linking and having covalently bonded active sites on the outer surface thereon. Such novel carrier being useful not only to link the novel peptide containing an amino acid chain with amino acids within the pre-S gene coded region of the surface antigen or hepatitis B virus, but can also be used to bind synthetic peptide analogues of other viral proteins, as well as bacterial, allergen and parasitic proteins of man and animals.
    Type: Grant
    Filed: April 14, 1989
    Date of Patent: April 20, 1993
    Assignees: New York Blood Center, Inc., California Institute of Technology
    Inventors: Alexander R. Neurath, Stephen B. H. Kent
  • Patent number: 5158769
    Abstract: A hepatitis B vaccine containing a peptide with an amino acid chain of at least six consecutive amino acids within the pre-S gene coded region of the envelope of hepatitis B virus. The vaccine being free of an amino acid sequence corresponding to the naturally occurring envelope proteins of hepatitis B virus and a physiologically acceptable diluent. The peptide being free or linked to a carrier. The carrier being a conventional carrier or a novel carrier including a lipid vesicle stabilized by cross-linking and having covalently bonded active sites on the outer surface thereon. Such novel carrier being useful not only to link the novel peptide containing an amino acid chain with amino acids within the pre-S gene coded region of the surface antigen of hepatitis B virus, but can also be used to bind synthetic peptide analogues of other viral proteins, as well as bacterial, allergen and parasitic proteins of man and animals.
    Type: Grant
    Filed: April 13, 1989
    Date of Patent: October 27, 1992
    Assignees: New York Blood Center, Inc., California Institute of Technology
    Inventors: Alexander R. Neurath, Stephen B. H. Kent
  • Patent number: 5120649
    Abstract: The present invention concerns a method of inactivating extracelluar lipid enveloped human pathogenic virus or intracelular human pathogenic virus in a blood cell-containing composition without incurring substantial disruption or inactivation of cells, comprising contacting a cell-containing composition having .gtoreq.1.times.10.sup.9 cells/ml and containing infectious virus with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of .gtoreq.630 nm, light and an oxidizer to substantially inactivate the virus to effect a virus kill of at least 10.sup.4 and to result in a retention of intact cell functionality and structure of greater than 80%. The present invention also is directed to a composition comprising human red blood cells suitable for transfusion at a concentration of .gtoreq.1.times.10.sup.9 cells/ml and having all extracellular lipid enveloped and intracellular human pathogenic viruses in a non-infectious form.
    Type: Grant
    Filed: May 15, 1990
    Date of Patent: June 9, 1992
    Assignee: New York Blood Center, Inc.
    Inventors: Bernard Horowitz, Jay E. Valinsky, Nicholas E. Geacintov, Bolanle Williams, Shanti B. Rywkin
  • Patent number: 5101017
    Abstract: A monoclonal antibody which identifies the human blood group Duffy (ab) is provided. Such monoclonal antibody blocks the penetration of P. vivax malaria parasite into human red blood cells by virtue of effective blocking of the target molecule of the P. vivax malaria parasite. Such monoclonal antibody has a combining site having the same stereochemistry as the ligand site on P. vivax, and elicits anti-idiotypic antibodies that react with the parasite.
    Type: Grant
    Filed: April 6, 1987
    Date of Patent: March 31, 1992
    Assignee: New York Blood Center, Inc.
    Inventors: Pablo Rubinstein, Margaret Nichols